National Cancer Institute - U.S. National Institutes of Health - www.cancer.govSkip navigationNational Cancer Institute - U.S. National Institutes of Health - www.cancer.govClinical Trials at NIH - Be part of the cure
National Cancer Institute - U.S. National Institutes of Health - www.cancer.gov
Clinical Trials at NIH Home

Clinical Trials by Cancer Site

Prostate Cancer

Prostate cancer is a disease that occurs when malignant (cancer) cells grow in the tissues of the prostate. The prostate is a gland in the male reproductive system found below the bladder and in front of the rectum.

It is unclear exactly what causes prostate cancer, although certain risk factors are linked to the disease:

  • Age: Prostate cancer is rarely seen in men younger than age 40; the chance of being diagnosed with prostate cancer goes up sharply as men get older
  • Race: Prostate cancer is more common among African American men than among men of other races, and African American men are also more likely to have more advanced disease when it is found; prostate cancer occurs less often in Asian American and Hispanic/Latino men than in non-Hispanic Whites
  • Family history: Men have an increased risk of prostate cancer if one or more of their first-degree relatives (i.e., father, brother, son) has prostate cancer, especially if the relative was diagnosed before age 60

Excluding non-melanoma cancers of the skin, prostate cancer is the most commonly diagnosed type of cancer among men in the United States. It is estimated that 238,590* men in the United States will be newly diagnosed with prostate cancer in 2013.

Treatment options for prostate cancer vary depending on the stage of disease, previous treatment and, other medical conditions. Talk with your doctor about what treatment options may be available for you.

*American Cancer Society. Cancer Facts and Figures 2013. Atlanta: American Cancer Society; 2013

Prostate Cancer Clinical Trials

The NCI Center for Cancer Research (CCR) conducts clinical trials at the NIH Clinical Center in Bethesda, Maryland. CCR is currently conducting the following trials for patients with prostate cancer. Click on the trials below for additional details, including a summary of key eligibility criteria, study outline, and information on how to contact the principal investigators and their staff directly. For information on a particular trial or to discuss a screening visit, contact a member of the research team listed on the trial’s summary.

If you need further assistance, call our toll-free number at 1-888-NCI-1937 (1-888-624-1937) to be connected to a referral coordinator appropriate for your diagnosis.


  
Trial and Protocol Number
Prostate Cancer
Phase III
A Randomized, Double-Blind, Phase III Efficacy Trial of PROSTVAC-V/F Plus or Minus GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer
NCI-11-C-0262, NCT01322490

Principal Investigator:Referral Contact:
James L. GulleyLaura D. Otten
301-435-2956301-451-1228
1-866-611-6310 (Toll Free)
ottenl@mail.nih.gov
Phase II
NaF PET/CT Repeatability, Responsiveness, and Response Assessment in Patients With Metastatic Castrate-Resistant Prostate Cancer to Bone Treated With Either Docetaxel-Based Chemotherapy or Androgen Receptor (AR)-Directed Therapies
NCI-12-C-0080

Principal Investigator:Referral Contact:
Andrea B. ApoloLaura D. Otten
301-496-4916301-451-1228
1-866-611-6310 (Toll Free)
ottenl@mail.nih.gov
A Phase II Study of AMG 386 and Abiraterone in Metastatic Castration Resistant Prostate Cancer
NCI-12-C-0079, NCT01553188

Principal Investigator:Referral Contact:
William L. DahutLaura D. Otten
301-435-8183301-451-1228
1-866-611-6310 (Toll Free)
ottenl@mail.nih.gov
A Randomized Phase II Study of L-BLP25 in Combination With Standard Androgen Deprivation Therapy and Radiation Therapy for Newly Diagnosed, High Risk Prostate Cancer Patients
NCI-11-C-0247

Principal Investigator:Referral Contact:
Ravi A. MadanLaura D. Otten
301-496-3493301-451-1228
1-866-611-6310 (Toll Free)
ottenl@mail.nih.gov
MR Image Guided Focal Therapy in Prostate Cancer
NCI-11-C-0158, NCT01377753

Principal Investigator:Referral Contact:
Peter A. PintoCelene Chua
301-496-6353301-402-4346
cchua@mail.nih.gov
Evaluation of Ferumoxytol Enhanced MRI for the Detection of Lymph Node Involvement in Prostate Cancer
NCI-11-C-0098, NCT01296139

Principal Investigator:Referral Contact:
Peter ChoykeYolanda McKinney
301-402-8409301-443-6913
ymckinney@mail.nih.gov
A Phase II Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
NCI-09-C-0195, NCT00942578

Principal Investigator:Referral Contact:
William L. DahutLaura D. Otten
301-435-8183301-451-1228
1-866-611-6310 (Toll Free)
ottenl@mail.nih.gov
A Randomized Phase II Trial Combining Vaccine Therapy With PROSTVAC/TRICOM and Flutamide vs. Flutamide Alone in Men With Androgen Insensitive, Non-Metastatic (D0.5) Prostate Cancer
NCI-07-C-0107, NCT00450463

Principal Investigator:Referral Contact:
Ravi A. MadanLaura D. Otten
301-496-3493301-451-1228
1-866-611-6310 (Toll Free)
ottenl@mail.nih.gov
Phase I/II
A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer
NCI-10-C-0062, NCT01090765

Principal Investigator:Referral Contact:
William L. DahutLaura D. Otten
301-435-8183301-451-1228
1-866-611-6310 (Toll Free)
ottenl@mail.nih.gov
Phase I
A Phase I Study of Cabozantinib (XL184) Plus Docetaxel and Prednisone in Metastatic Castrate Resistant Prostate Cancer
NCI-12-C-0204 , NCT01683994

Principal Investigator:Referral Contact:
William L. DahutLaura D. Otten
301-435-8183301-451-1228
1-866-611-6310 (Toll Free)
ottenl@mail.nih.gov


  
Trial and Protocol Number
Solid Tumor
Phase II
Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 TCR-Gene Engineered Lymphocytes
NCI-08-C-0121, NCT00670748

Principal Investigator:Referral Contact:
Steven A. RosenbergJune A. Kryk
1-866-820-4505 (Toll Free)1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov
Phase I/II
Phase I/II Study of Metastatic Cancer that Expresses MAGE-A3/12 Using Lymphodepleting Conditioning Followed by Infusion of Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes
NCI-11-C-0062, NCT01273181

Principal Investigator:Referral Contact:
Steven A. RosenbergJune A. Kryk
1-866-820-4505 (Toll Free)1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov
Phase I
A Phase I, Open-label, Multiple-Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C, a Monoclonal Anti-PD-L1 Antibody, in Adults With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
NCI-13-C-0063, NCT01772004

Principal Investigator:Referral Contact:
James L. GulleyLaura D. Otten
301-435-2956301-451-1228
1-866-611-6310 (Toll Free)
ottenl@mail.nih.gov
A Phase I Study of an Adenoviral Transduced Autologous Dendritic Cell Vaccine Expressing Human HER2/neu ECTM in Adults With Tumors With 1-3+ HER2/neu Expression
NCI-13-C-0016, NCT01730118

Principal Investigator:Referral Contact:
Lauren V. WoodBrenda Roberson
301-402-0199301-435-4733
broberson@mail.nih.gov
An Open Label Phase I Study to Evaluate the Safety and Tolerability of GI-6301 Vaccine Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express Brachyury Protein in Adults With Solid Tumors
NCI-12-C-0056, NCT01519817

Principal Investigator:Referral Contact:
James L. GulleyLaura D. Otten
301-435-2956301-451-1228
1-866-611-6310 (Toll Free)
ottenl@mail.nih.gov
Phase I Trial of Z-Endoxifen in Adults With Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or other Hormone Receptor-Positive Solid Tumors
NCI-11-C-0061, NCT01273168

Principal Investigator:Referral Contact:
Shivaani KummarJanelle Bingham
301-435-0517301-435-2715
jbingham@mail.nih.gov
No Phase
A Natural History Study of Patients Receiving High Dose Rate Brachytherapy
NCI-09-C-0100, NCT00924027

Principal Investigator:Referral Contact:
Aradhana KaushalSharon L. Smith
301-496-5457301-496-5457
smiths@mail.nih.gov


Back to Top
Health and Human Services National Institutes of Health National Cancer Institute USA.gov